NEW YORK, March 5, 2018 —
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on MNK, MNTA, MYL, and NBIX which can be accessed for free by signing up to www.wallstequities.com/registration. Featured today on WallStEquities.com is the Generic Drugs space, which can be segmented into biosimilars, simple generic, and super generic. Under evaluation this morning are the following stocks: Mallinckrodt PLC (NYSE: MNK), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), Mylan N.V. (NASDAQ: MYL), and Neurocrine Biosciences Inc. (NASDAQ: NBIX). All you have to do is sign up today for this free limited time offer by clicking the link below.
Staines-Upon-Thames, the UK headquartered Mallinckrodt PLC's shares recorded a trading volume of 6.46 million shares last Friday, which was above their three months average volume of 3.66 million shares. The stock finished the trading session 4.02% higher at $16.31. The Company's shares are trading below their 50-day moving average by 18.50%. Furthermore, shares of Mallinckrodt, which develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies in the US, EMEA region, and internationally, have a Relative Strength Index (RSI) of 41.87.
On February 15th, 2018, Mallinckrodt announced that it will present on March 14th, 2018, at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel, 1601 Collins Ave. in Miami Beach, Florida. Matthew Harbaugh, Executive Vice President and CFO, and Steven Romano, M.D., Executive Vice President and Chief Scientific Officer, will represent the Company in a fireside chat at 10:15 a.m. ET that day. Get the full research report on MNK for free by clicking below at: www.wallstequities.com/registration/?symbol=MNK
On Friday, Cambridge, Massachusetts headquartered Momenta Pharmaceuticals Inc.'s stock ended the session 2.03% higher at $17.55. A total volume of 702,683 shares was traded. The Company's shares have gained 3.24% in the last month, 25.36% over the previous three months, and 18.58% over the past year. The stock is trading 12.67% above its 50-day moving average and 13.44% above its 200-day moving average. Moreover, shares of Momenta Pharma, which focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the US, have an RSI of 60.41.
On February 13th, 2018, Momenta Pharma (MNTA) announced that the US FDA has approved Sandoz's Abbreviated New Drug Application for Glatopa (glatiramer acetate injection) 40 mg/mL, and that Sandoz has initiated the launch of this product in the US. Glatopa was developed under a collaboration agreement between MNTA and Sandoz and is produced in the US.
On February 22nd, 2018, research firm Stifel upgraded the Company's stock rating from 'Hold' to 'Buy' while revising its previous target price from $18 a share to $21 a share. The free technical report on MNTA can be accessed at: www.wallstequities.com/registration/?symbol=MNTA
Hatfield, the UK-based Mylan N.V.'s stock ended the day 0.69% higher at $40.97. A total volume of 7.05 million shares was traded, which was above their three months average volume of 6.08 million shares. The Company's shares have gained 11.15% over the previous three months. The stock is trading 7.83% above its 200-day moving average. Additionally, shares of Mylan, which together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide, have an RSI of 45.01.
On February 28th, 2018, Mylan announced that its CFO, Ken Parks, will present at the Raymond James 39th Annual Institutional Investors Conference on March 05th, 2018, at 1:40 p.m. ET in Orlando, Florida. The live webcast of the presentation can be accessed under the investor relations section of the Company's website. Sign up for free on Wall St. Equities and claim the latest report on MYL at: www.wallstequities.com/registration/?symbol=MYL
Shares in San Diego, California headquartered Neurocrine Biosciences Inc. recorded a trading volume of 841,705 shares. The stock ended Friday's session 2.28% higher at $86.06. The Company's shares have gained 0.69% in the last month, 25.82% over the previous three months, and 94.79% over the past year. The stock is trading above its 50-day and 200-day moving averages by 6.02% and 36.87%, respectively. Furthermore, shares of Neurocrine Biosciences have an RSI of 56.60.
On February 13th, 2018, Neurocrine Biosciences announced its Q4 and year-end 2017 results. For Q4 2017, net income was $6.9 million; R&D expenses were $25.6 million; and sales, general and administrative (SG&A) expenses were $56.3 million. For the full year 2017, net loss was $(142.5) million, R&D expenses were $121.8 million, and SG&A expenses were $169.9 million. At December 31st, 2017, total assets were $817.6 million, including cash, investments and receivables of $797.6 million.
On February 22nd, 2018, research firm Needham reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $95 a share to $110 a share. See the free research coverage on NBIX at: www.wallstequities.com/registration/?symbol=NBIX
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFAÂ® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFAÂ® and Chartered Financial AnalystÂ® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-generic-drugs-stocks—-mallinckrodt-momenta-pharma-mylan-and-neurocrine-biosciences-300607914.html
SOURCE Wall St. Equities